(Source: VBL Therapeutics Ltd) TEL AVIV, Israel, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ('VBL Therapeutics' or the 'Company') (NASDAQ:VBLT), today announced the pricing of an underwritten offering of 2,500,000 ordinary shares together with accompanying warrants to purchase an aggregate of 1,250,000 ordinary shares. The combined offering price of each ordinary share and accompanying warrant was $6.00 per share. The gross proceeds to VBL Therapeutics from this offering are expected to be $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by VBL Therapeutics. The warrants will be exercisable at $7.50 per share,...
↧